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Introduction:Wereport an “instant kit”method to radiolabelﬂuorescent-tilmanoceptwith 68Ga and 99mTc for tri-
modal molecular imaging of sentinel lymph nodes (SLNs).
Methods: Solutions of sodium acetate, 68GaCl3 and Na99mTcO4 were added successively to a “kit vial” containing ly-
ophilized 800CW-tilmanocept, SnCl2, trehalose and ascorbic acid. After a 30-min incubation, the pHwas neutralized
with PBS. No puriﬁcation was required. Radiochemical and ﬂuorescence purity was measured by HPLC and ITLC
techniques. In vitro stability was measured by standing gel chromatography (SGC) and ITLC by a 100-fold dilution
0.25 h after radiolabeling. In vivo stabilitywasmeasured by SGC and ITLC after an 11 h incubation in human plasma.
A dose (0.1 nmol, ~1 MBq 68Ga, ~25MBq 99mTc) was injected to the footpad of 4mice. Popliteal SLNs were imaged
by PET and ﬂuorescence imaging systems at 0.5, 24, 48, 72 h, then excised and assayed for 99mTc.
Results:Radiochemical andﬂuorescent purity exceeded98%. The in vitro stability assaydemonstratedhigh irreversibility
of both radiolabels and theﬂuorescent label, and invivo stability assaydemonstratedhighstability of the technetiumand
ﬂuorescent labels to plasmametabolism. Popliteal SLNswere identiﬁed by PET andﬂuorescence imagingwithin 0.5 h of
injection. SLN ﬂuorescence intensity remained constant for 72 h, when ~1% of the injected dose resided in the SLN.
Conclusions: Fluorescent-labeled tilmanocept can be radiolabeledwith 68Ga and 99mTc by the sequential addition of each
generator eluate to a lyophilized kit. The resulting tri-modal agent provides: PET images for pre-operative SLNmapping,
ﬂuorescence imaging up to 72 hours after injection, and quantitative radiometric measurement of SLN accumulation
after excision.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
In 2013 technetium-99m-labeled tilmanocept (tradename
Lymphoseek) was approved for lymphatic mapping by the U.S. Food
and Drug Administration [1]. This radiopharmaceutical has a receptor
binding motif, mannose, which is the substrate to CD206, a receptor
expressed on the surface of macrophages [2,3] and dendritic cells [4].
The radiopharmaceutical demonstrated high concordance with vital
blue dye, with rapid SLN accumulation and sustained SLN retention in
series of clinical trials [5–10].
Recent developments in sentinel lymph node (SLN) mapping sug-
gest the need for a multi-modal contrast agent that provides both
cross-sectional images for pre-surgical planning and intra-operative
mapping [11] via ﬂuorescence detection. We recently characterized a
bi-modal SLN targeting agent 68Ga-800CW-tilmanocept [12] based on
positron emission tomography (PET) and ﬂuorescence imaging. PET im-
aging with 68Ga provided a quantitative pre-operative map for surgical
planning based on standard uptake value (SUV) measurements [13]., 3855 Health Sciences Drive, La
58 246 0594.
. This is an open access article underTo further its clinical application, here we describe a method to ra-
diolabel 800CW-tilmanocept with both 68Ga and 99mTc. This agent inte-
grates three imaging reporters: 68Ga, 99mTc, and IRDye800CW. Our goal
is an instant radiolabeling kit that will result in a diagnostic imaging
agent that can provide quantitative pre-operative PET/CT imaging and
intra-operative sentinel lymph node mapping that is compatible with
robotic-assisted surgery that is not constrained by a radionuclidic
half-life. Lastly, we desire a radioactive label, such as 99mTc, that can
be used to quantitate sentinel lymph node uptake. This last feature
will be important during early phase clinical trials, which will require
measurements of tilmanocept biodistribution at early and late time
points and the determination of ﬂuorescent dye accumulation within
the sentinel lymph node at the time of surgery.2. Materials and methods
2.1. Materials
IRDye800CW-tilmanocept was prepared as previously described
[12]. It exists as a dextran backbone (10.5 kDa) conjugated with various
functional groups. On average, each dextran molecule is modiﬁed withthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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and 99mTc, 2.3 molecules of the optical imaging reporter IRDye800CW,
16.8 molecules of mannose, the receptor substrate, and 3.2 units of pri-
mary amines.
L-ascorbic acid crystalline powder USP was purchased from Spec-
trum Chemical (Gardena, CA).α,α- trehalose dihydrate was purchased
fromUSB Corporation (Cleveland, OH). Saline, 0.9% Sodium Chloride In-
jection USP, and Sodium Acetate Injection USP were purchased from
Hospira. Inc (Lake Forest, IL). Prepacked PD MiniTrap G-10 columns
(GE Healthcare Bio-Sciences, Pittsburgh PA) were purchased and
equilibrated as directed. Whatman 31ET and SG81 chromatography
paper were both purchased from GE Healthcare Bio-Sciences (Pittsburgh
PA). All other chemicals were commercially available and used with-
out further puriﬁcation. Human plasma was obtained from San
Diego Blood Bank.
2.2. Dual-radiolabeling of 800CW-tilmanocept with 68Ga and 99mTc
Lyophilized radiolabeling kits were prepared in the following man-
ner. All work was performed in a HEPA-ﬁltered “clean bench”. Solution
A was prepared as a mixture of 100 mg trehalose, 2.5 mg ascorbic acid
and 4.5 mL saline in a sterile 15 mL centrifuge tube. Solution B was pre-
pared as amixture of 15mgSnCl2, 0.175mL 37%HCl and 20mL saline in
a sterile 50 mL centrifuge tube. An aliquot of 0.08 mL of 800CW-
tilmanocept stock solution (8 nmol) and 0.1 mL of Solution B were
added to a 10 mL amber glass serum vial (Wheaton, Millville, NJ).
After bubbling nitrogen gas into solution A for 20 minutes, 0.9 mL of
the solution was added into each of the vials containing 800CW-
tilmanocept and solution B. The vials were allowed to cool rapidly in a
stainless steel tray containing dry ice and acetone. Immediately after
freezing, slotted rubber septa (Wheaton, Millville, NJ) were placed
atop each vial; the vials were then quickly transferred into a cold vacu-
umchamber equippedwith a deﬂated rubber bladder positioneddirect-
ly above the unsealed stoppers. After reaching a constant vacuum
(b100 μm Hg), the vacuum chamber was backﬁlled with ﬁltered
argon (Ultra high purity, Airgas, San Diego, CA), and the septa atop the
vials were depressed by expanding the rubber bladderwith a gentle de-
livery of laboratory air. After crimping the septawith aluminum ﬂip-cap
seals, the vials were stored in the dark at−20 °C.
Radiolabeling of 99mTc and 68Ga proceeded in a sequential fashion.
Prior to the addition of each radioisotope to the labeling vial, each sy-
ringe containing the 99mTc or 68Ga generator eluate was assayed in a
dose calibrator CRC-15 W (Capintec, Inc., New Jersey) using the appro-
priate radionuclide setting. 99mTc Sodium Pertechnetate Injection
(~1.5 GBq, 0.2mL) (Cardinal Health, SanDiego, CA)was added to the la-
beling vial containing the lyophilized product with an insulin syringe.
During a 15-minute reaction period, the 68Ga generator (IGG100, Eckert
& Ziegler Isotope Products, Berlin, Germany)was elutedwith 5mL 0.1N
HCl prepared with high purity hydrochloric acid (Sigma-Aldrich, St.
Louis, MO) and OmniTrace Ultra high purity water (EMD Millipore,
Billerica, MA) in a 60 ml sterile syringe. The 68Ga generator was previ-
ously eluted with 5 mL HCl within 24 h prior to this elution. A sodium
acetate solution (2 M, 0.08 mL) was added aseptically to the labeling
vial using a sterile 0.3 mL insulin syringe. Immediately after mixing,
68Ga eluate (150 MBq, ~0.8 mL) was transferred to the labeling vial
with an insulin syringe. After brief swirling, the reactionmixturewas in-
cubated at room temperature for 10 minutes. Finally, Phosphate-
Buffered Saline USP (Mediatech, Inc., Herndon, VA)was added to obtain
the ﬁnal volume of 2.2 mL. A small portion of the product was removed
via a sterile syringe for quality control.
2.3. Quality control and stability tests
2.3.1. Measurement of radiochemical and ﬂuorescent purity
Radiochemical andﬂuorescent purityweremeasured by instant thin
layer chromatography (ITLC) using Whatman-31ET (GE Healthcare,Bio-Sciences, Pittsburgh PA) as the stationary phase and acetone as
the mobile phase. The strip was air-dried and scanned with a radio-
TLC imaging scanner (Bioscan AR 2000, Eckert & Ziegler Radiopharma
Inc., Hopkinton MA). A Fluobeam 800 (Fluoptics, Grenoble, France)
hand-held ﬂuorescence imager (Excitation: 780 nm; Emission: 800 nm
long pass) was used to measure the distribution of ﬂuorescence on
the developed strip. The ﬂuorescent image was analyzed with ImageJ
software (National Institutes of Health, Bethesda, MD). Normalization
was performed through dividing each radioactivity or ﬂuorescence
measurement by the highest value. The normalized ﬂuorescence inten-
sity and radioactivity values were plotted against the distance traveled
by the solvent.
2.3.2. Standing gel chromatography
The radioactivity proﬁle of the radiolabeled compound was charac-
terized by standing gel chromatography (SGC). Prepacked PD MiniTrap
G-10 columns were shaken, the stationary phase was allowed to settle,
and the column was rinsed twice with DI water. A new column is used
for each assay. A small aliquot (50 μL) of the radiolabeled product was
applied to the top of the column. Then distilled water (550 μL) was
added. The liquid was allowed to enter the packed bed completely. Fi-
nally, the column containing radiolabeled compound was scanned
with the Fluobeam 800 and Bioscan AR 2000 scanner.
2.3.3. In vitro stability assay
The irreversibility of the radiolabelingwas tested by a dilution assay.
A small aliquot (10 μL) of the radiolabeled compound was diluted with
isotonic PBS (990 μL) with orwithout the presence of 0.05 μMethylene-
diaminetetraacetic acid (EDTA), resulting in a 100-fold dilution of the
radiolabeled product. The chelating agent was added to capture the dis-
sociated radioactive metal. Upon brief shaking, this mixture was incu-
bated at room temperature for 15 minutes. A small aliquot (50 μL) of
themixturewas removed, and the radioactivity andﬂuorescence proﬁle
were measured with the SGC technique described above. Two ITLC sys-
temswere also employed usingWhatman 31ET chromatography paper
as the stationary phase and acetone as the mobile phase, and SG81 as
the stationary phase and saline as the mobile phase.
2.3.4. In vivo stability assay
In order to evaluate the in vivometabolism, the radioactivity pro-
ﬁle of the compound was investigated after incubation with PBS or
human plasma. A portion of the freshly radiolabeled compound
(100 μL) was incubated with 900 μL PBS or human plasma at 37 °C.
After 11 hours, a small aliquot (50 μL) of each solution was applied to
a G-10 column. SGC technique was used to measure the radioactivity
and ﬂuorescence proﬁle.
2.4. Multi-modal SLN imaging
2.4.1. Determination of injected 68Ga and 99mTc radioactivity
Prior to adding the radioactivity to the labeling vial, syringes con-
taining 68Ga and 99mTcweremeasured separatelywith the dose calibra-
tor. Decay correction was applied to calculate the radioactivity of each
radioisotope at the time of injection. This determination required that
the injectate did not undergo a puriﬁcation step and that all of the radio-
activity was bound to 800CW-tilmanocept.
2.4.2. In vivo imaging
Four female Swiss Webster mice (20–24 g, 4 wks of age) were pur-
chased fromHarlan Laboratories (Indianapolis, IN) and housed at desig-
nated vivarium with standard diet. All in vivo procedures in this study
were performed under a protocol approved by the Institutional Animal
Care and Use Committee at University of California, San Diego. Anesthe-
sia was induced by inhalation of 1–2% isoﬂuorane. The lower abdomen
area and both legs were shaved. Using a 28 gauge insulin syringe, all an-
imals received a subcutaneous injection of 68Ga- and 99mTc-labeled
Fig. 2. Instant thin layer chromatography (ITLC) of 68Ga- and 99mTc-labeled 800CW-
tilmanocept demonstrated high radiochemical and ﬂuorescent purity. Radioactivity
(red) and ﬂuorescence (blue) chromatograms reveal greater than 98% of the radioactivity
and ﬂuorescence at the origin. Unbound pertechnetate, free gallium, and IRDye800CW
move with the solvent front.
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the left hind side of the footpad. The injection site was massaged for
10 seconds immediately after the injection.
Five minutes after injection, mice were positioned with the footpad
and the popliteal node within the ﬁeld of view and imaged (10 minutes)
with a PET scanner (eXplore Vista DR, GE Healthcare, Waukesha, WI),
using a 400–700 keV energy window. At 30 minutes post injection,
themicewere transferred to the imaging stage of a ﬂuorescence imager
OptixMX (Advanced Research Technologies Inc., Montreal, Canada). The
laser excitation and emission wavelengths were adjusted to 758 nm
and 780–792 nm respectively. An ROI was selected over the sentinel
lymph node with a 1.5 mm × 1.5 mm pixel size. Fluorescence scans
were repeated at 24, 48 and 72 h post injection. Images were viewed
and analyzed with standard OptiView software (Advanced Research
Technologies Inc., Montreal, Canada). After the 72 h imaging session,
the popliteal SLNs were excised and assayed for 99mTc radioactivity in
a gamma well counter (Gamma 9000 Beckman Instruments, Fullerton,
CA) with an energy window of 100–200 keV. Counting standards
were prepared by diluting a known volume of the injectate.
3. Results
3.1. Quality control and stability tests
3.1.1. Radiochemical purity and ﬂuorescent purity
The radiolabeling yield and radiochemical purity for the 68Ga-
& 99mTc- labeled product (Fig. 1) were in excess of 99% as measured
by ITLC. The ITLC strips exhibited no radioactivity or ﬂuorescence at
the solvent front (Rf ~4 cm), which is the migration pattern for 99mTc
pertechnetate and IRDye800CW carboxylate [12]. Radioactivity and
ﬂuorescence remained at the origin of the ITLC chromatogram (Fig. 2).
The co-localization of ﬂuorescence and radioactivity signals was consis-
tent with previous observations [12].
3.1.2. Irreversibility assay
The radioactivity and ﬂuorescence proﬁles of the undiluted product
were similar to the 100-fold dilution of the product (Fig. 3A). After the
100-fold dilution, 68Ga- and 99mTc-labeled 800CW-tilmanocept samples
exhibited a single radioactivity and radioactivity peak at the same posi-
tion (~2.3 cm) on the G-10 column. On both the Whatman 31ET and
SG81 ITLC systems, only one radioactivity peak was detected, which
was at the origin. The developed Whatman 31ET strips of undiluted
and 100-fold diluted samples did not demonstrate radioactivity at the
solvent front, where the 99mTc pertechnetate or free 68Ga migrate. Ra-
dioactivity was not detected at the solvent front of the SG81 strips,
where 99mTc-EDTA or 68Ga-EDTA travel [14]. The radioactivity andFig. 1. Chemical structure of 68Ga- and 99mTc-labeled 800CW-tilmanocept. The receptor binding tr
reporters, 68Ga and 99mTc, the optical imaging reporter IRDye800CW (NDye = 2.3), mannose (NM =ﬂuorescence peaks of the diluted samples exhibited a broader distribu-
tion due to its weak signal (Fig. 3B).
3.1.3. In vivo stability assay
After incubationwith PBS (Fig. 4A) or human plasma (Fig. 4B), 68Ga-
and 99mTc-labeled 800CW-tilmanocept samples exhibited single radio-
activity peak (~2.3 cm) on the G-10 columns. The corresponding ﬂuo-
rescence peaks presented at the same locations in the G-10 column.
No unbound radioactivity or ﬂuorescence was detected at the top, bot-
tom, or eluate of the columns.
3.2. SLN imaging in mice
As demonstrated in the maximum intensity projection of a coronal
PET image (Fig. 5A), the injection site (solid arrow) and popliteal SLN
(open arrow) were shown as “hot” spots. The 10-minute PET image
was started 10 minutes after injection. The color map was generated
in SUV units. The SLN had an SUV value of 7, and the injection site
SUV was 23. Fig. 5B is a fused image with bright ﬁeld and ﬂuorescence,
acquired 10 minutes after completion of the PET scan of Fig. 5A. Strong
ﬂuorescence signal in popliteal SLN (open arrow) was detected. As
shown in Fig. 6A, the mean value (n = 4) of the ﬂuorescence intensity
(2.0 ± 0.17 kcts/s at 0.5 h, 2.0 ± 0.46 kcts/s at 24 h, 1.8 ± 0.46 kcts/s
at 48 h and 1.9 ± 0.26 kcts/s at 72 h) in popliteal lymph node did not
change signiﬁcantly within a time frame of 72 h. The signal remained
strong after 72 h, as demonstrated in Fig. 6B, which is a ﬂuorescence
image, acquired 71 h after Fig. 5B. Based on the ex vivo nuclear countingi-modal imaging probe is composed of DTPA (ND=4.4), which chelate the gamma imaging
16.8), the receptor substrate, and unmodiﬁed amino-terminated leashes (NA = 3.2).
Fig. 3. Radioactivity (red) and ﬂuorescence (blue) standing gel chromatography of
(A) undiluted 68Ga- and 99mTc-labeled 800CW-tilmanocept and (B) product diluted 100-
fold with an EDTA/PBS solution. Radioactivity was not detected at the top of the column in-
dicating the absence of hydrolyzed 99mTc or hydrolyzed 68Ga. Radioactivity was not detect-
ed at the solvent front of ITLC strips indication the absence of 99mTc-EDTA or 68Ga-EDTA.
Fig. 4. Radioactivity (red) and ﬂuorescence (blue) standing gel chromatography
(Pertechnetate, Tc-EDTAelutewith Tc-tilmanocept)of radiolabeled 68Ga- and 99mTc-labebeled
800CW-tilmanocept, after 11 hour incubation in (A) PBS or (B) human plasma at 37 °C.
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in the excised popliteal SLNs at 72 h post-injection. The %ID of the SLN in
Fig. 6B was 0.9%.
4. Discussion
This work demonstrated the following features of the tri-modal
tilmanocept. First, the ﬂuorescent-tilmanocept precursor was dual-
radiolabeled with 68Ga and 99mTc using an “instant-kit”. Second, tri-
modal SLN imaging was demonstrated with PET and ﬂuorescence, and
the accumulation of the probe by sentinel lymph nodes was quantiﬁed
by the second radiolabel. And third, the SLN ﬂuorescence intensity
remained strong for 72 h.
The ﬂuorescence proﬁle of IRDye800CW is compatible with the Fire-
ﬂy illumination/camera system of the Da Vinci surgical robot. In prepa-
ration for intra-operative imaging of canine prostate sentinel lymph
nodes with ﬂuorescent-labeled tilmanocept, we radiolabeled 800CW-
tilmanocept with 99mTc and imaged rabbit popliteal lymph nodes with
Fireﬂy system using different tilmanocept doses, imaging times, and
camera conﬁgurations [15]. After footpad injection of 99mTc-labeled
800CW-tilmanocept, popliteal SLNs were identiﬁed up to 36 hours
post injection at two differentmolar doses. Technetium-99mmeasure-
ments of the popliteal and para-aortic lymph nodes demonstrated that
the uptake was accomplished without receptor saturation of the SLN.
Based these results, a dual radiolabeled version of ﬂuorescent
tilmanocept was used to perform robotic-assisted sentinel lymph
node mapping in the dog model. Tilmanocept labeled with theﬂuorescent dye IRDye-800CW, 68Ga, and 99mTc was injected into the
prostate gland of a beagle. Based on preoperative PET/CT images, the
Fireﬂy camera of the surgical robot easily detected all of the SLNs
36 hours after transrectal injection [16].
A single administration of this tri-modal imaging agent can aid pre-
operative planning and intra-operative guidance. The PET modality, in
conjunction of CT, provides a cross-sectional map of the sentinel
lymph node basins. The SLN accumulation of the radiopharmaceutical
can be measured by SUVs before surgery. This is important because
each lymph node in the image must to be qualiﬁed as a SLN prior to
its excision. This is typically accomplished by requiring the SLN be at
least a ﬁxed percentage (usually 10%) of the “hottest” SLN. It is well doc-
umented that pre-operative imaging facilitates rapid localization of the
hot nodes and saves time in the operating room [17]. The 6-hour long
half lived 99mTc, enabled the ex-vivo quantiﬁcation of the excised
lymph nodes. Lastly, the strong near-IR emission permitted in vivo de-
tection of the SLNs during surgery.
We introduced a ﬂuorescence reporter that permits intra-operative
detection many days after injection. This agent is compatible with a
widely used robotic-assisted surgical system,which detects the ﬂuores-
cence signal with a ﬂuorescence-capable camera system. Therefore,
ﬂuorescent SLNs could be visualized laparoscopically during the sur-
gery. Consequently,ﬂuorescent-labeled tilmanocept is an excellent con-
trast agent for minimally invasive SLN surgery. Unlike the nuclear
imaging, ﬂuorescence imaging reporters have no half-life and, in the ab-
sence of metabolism, can provide intra-operative imaging many days
after administration. However, ﬂuorescence imaging reporters are not
quantitative; the amount of ﬂuorophore within tissue cannot be deter-
mined accurately by ﬂuorescence intensitymeasurements. Consequently,
Fig. 5. PET and ﬂuorescence sentinel lymph node imaging in amouse after footpad injection of 68Ga- and 99mTc-labeled 800CW-tilmanocept. (A) At 15minutes post injection a maximum
intensity projection coronal image demonstrated an injection site and popliteal lymph node with SUVs of 27 and 7, respectively; (B) A ﬂuorescence image 30 min after injection demon-
strated strong ﬂuorescence signals for both injection site (solid arrow) and popliteal SLN (open arrow). Color map represents normalized ﬂuorescence intensity in units of counts per sec-
ond per microWatt.
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lation and calculation of the amount of ﬂuorophore delivered. Such
measurements will be critical during early phase clinical trials of
the ﬂuorescent-probe.
The stability of 68Ga- and 99mTc-labeled 800CW-tilmanocept was
conﬁrmed by testing the irreversibility of the three imaging reporters
and the in vivo metabolism in human plasma. In the diluted solution,
EDTAwas added to chelate any dissociated 99mTc and 68Ga ions. Assum-
ing there is an equilibrium for the coordination reaction between the ra-
dioactive metal ions and tilmanocept, according to Le Chatelier's
principle, the equilibrium would shift to the dissociation direction
upon dilution. The released radioactive metal ions would be then
bound by the strong chelator, EDTA. Technetium-99 m-EDTA and
68Ga-EDTA migrate with the solvent front in the SG/saline ITLC system
[14,18]. The absence of any peak at this location indicated that no
metal-EDTA complexes were formed. Dissociation did not occur in the
100-fold dilution, indicating strong radioisotope binding by
tilmanocept. Also, the radiolabeled compound was stable for at least
11 hours in human plasma at 37 °C. No unbound radioactivity was de-
tected after incubation. Human plasma was used to mimic the physio-
logical environment of the subcutaneously injected dose. The non-
cellular composition within the lymph approximates that of blood
[19,20]. On all developed strips and standing gel columns, the ﬂuores-
cence distribution always co-localized with the radioactivity proﬁle.
The ﬂuorophore, IRDye800CW, was covalently attached to tilmanocept.
No dissociated (free) ﬂuorophore was observed by ITLC or SGC after
radiolabeling and after 11 h in PBS or plasma.Fig. 6.High ﬂuorescence intensity in popliteal sentinel lymph node (SLN) was unchanged from
intensity of 2 kcps between 0.5 and 72 h. (B) Fluorescence image at 72 h post injection. StrongThe structure of tilmanocept has been optimized for integration of ra-
dioactivity and ﬂuorescence reporters. If a standard tilmanocept dose of
3.0 nmol is radiolabeledwith 2mCi of 68Ga (~0.74 pmol 68Ga atoms) and
2 mCi of 99mTc (~3.8 pmol 99mTc atoms), only 0.03% of the DTPA groups
will be occupied. The extra chelation sites promote the radiolabeling ki-
netics. An additional optimization pertained to the ﬂuorophore density.
The highest ﬂuorescence brightness is achieved with an average of two
molecules of IRDye800CW are attached to each tilmanocept [12]. A
higher density would result in quenching, while fewer dyes per
tilmanocept would generate a weaker ﬂuorescence signal.
In the ﬁnal dose for in vivo imaging, the radioactivity of 68Ga and 99mTc
cannot be directlymeasured independentlywith the dose calibrator. In-
stead, it was calculated based on the individual radioactivity prior to
radiolabeling and decay-corrected. From all ITLC or SGC characteriza-
tions, no unbound radioactivity in the product was observed. The
assumption of a 100% labeling yield was applied to perform the
dose calculation.
To the best of our knowledge, this is the ﬁrst example of a dual
radiolabeled ﬂuorescent molecular imaging agent. Successful radiolabeling
with high radiochemical purity was achieved without the need for
puriﬁcation. This provided a facile method to determine the injected
amount of 68Ga and 99mTc. The ability to obtain early and late
(24 hours) whole body scans, as well as accurate determination of
ﬂuorophore uptake within the target tissue will be required for a
phase 1 clinical trial. Finally, this work conﬁrms that ﬂuorescence signal
is retained by the SLN for at least 3 days. The high correlation of ﬂuores-
cent nodes detected during surgery and radioactive nodes by PET0.5 to 72 h after injection. (A) Popliteal SLNs (n= 4) maintained an average ﬂuorescence
signal observed in injection site (solid arrow) and popliteal SLN (open arrow).
922 Z. Qin et al. / Nuclear Medicine and Biology 42 (2015) 917–922imaging that was observed in the mouse model is consistent with pre-
vious imaging of the rabbit [15], canine [16] models. This property
may allow patients to be pre-operatively imaged by PET/CT within an
hour of administration followed by surgery many days or weeks later.
The lack of a physical half-life by the ﬂuorescence reporter provides
ﬂexibility in coordinating pre-operative imaging and the surgery.
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